<p>Intellia Therapeutics, Inc.（纳斯达克代码：NTLA - 获取免费报告）在周五的午盘交易中股价下跌了 4.3%。该股票最低交易价为 8.93 美元，最后交易价为 9.06 美元。在交易中，共成交 436,341 股，较平均交易量 2,550,550 股下降了 83%。该股票此前收盘价为 9.46 美元。</p>
<p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
<p>NTLA 一直是多份分析师报告的主题。Guggenheim 将 Intellia Therapeutics 的目标价从 55.00 美元下调至 45.00 美元，并在 5 月 12 日的报告中给予该股票 “买入” 评级。HC Wainwright 在周二的研究报告中重申了 “买入” 评级，并对 Intellia Therapeutics 的股票设定了 30.00 美元的目标价。Wolfe Research 在 4 月 21 日的研究报告中将 Intellia Therapeutics 的股票评级从 “同业表现” 上调至 “跑赢大盘”，并设定了 21.00 美元的目标价。Barclays 在 2 月 28 日的报告中将 Intellia Therapeutics 的目标价从 55.00 美元下调至 26.00 美元，并给予该股票 “增持” 评级。最后，Wall Street Zen 在 3 月 3 日的研究报告中将 Intellia Therapeutics 的股票评级下调至 “卖出”。两位分析师给予该股票 “卖出” 评级，六位给予 “持有” 评级，十三位给予 “买入” 评级，还有一位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，Intellia Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 36.90 美元。</p>
<p><strong>查看我们对 NTLA 的最新股票分析</strong></p>
<h2>Intellia Therapeutics 股票表现</h2>
<ul>
<li>2 只基因编辑股票有望在 2025 年强势反弹</li>
</ul>
<p>该公司的市值为 9.5037 亿美元，市盈率为-1.68，贝塔值为 2.33。该公司的 50 日移动平均价格为 7.98 美元，200 日移动平均价格为 10.63 美元。</p>
<p>Intellia Therapeutics（纳斯达克代码：NTLA - 获取免费报告）最近在 5 月 8 日发布了其财报。该公司报告本季度每股收益为（1.10 美元），超出市场共识预期的（1.26 美元）0.16 美元。该公司本季度的收入为 1663 万美元，而分析师预期为 1139 万美元。去年同期，该公司每股收益为（1.12 美元）。Intellia Therapeutics 的收入同比下降了 42.6%。平均而言，股票研究分析师预计 Intellia Therapeutics, Inc.在当前财年将发布每股收益为-5.07 美元。</p>
<h2>机构投资者对 Intellia Therapeutics 的看法</h2>
<ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
<p>一些机构投资者最近增加或减少了对该股票的持股。Barclays PLC 在第三季度将其在 Intellia Therapeutics 的持股增加了 17.7%。Barclays PLC 现在拥有 292,795 股该公司的股票，价值 6,017,000 美元，此前在上个季度又购买了 44,022 股。SG Americas Securities LLC 在第四季度将其在 Intellia Therapeutics 的持股增加了 85.7%。SG Americas Securities LLC 现在拥有 44,838 股该公司的股票，价值 523,000 美元，此前在上个季度又收购了 20,694 股。KBC Group NV 在第四季度将其在 Intellia Therapeutics 的持股增加了 62.4%。KBC Group NV 现在拥有 6,093 股该公司的股票，价值 71,000 美元，此前在此期间又收购了 2,340 股。中国泛海资产管理有限公司在第四季度将其在 Intellia Therapeutics 的持股增加了 10.5%。中国泛海资产管理有限公司现在拥有 21,596 股该公司的股票，价值 252,000 美元，此前在此期间又收购了 2,059 股。最后，Empowered Funds LLC 在第四季度收购了 Intellia Therapeutics 的新股份，价值 185,000 美元。88.77% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Intellia Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Intellia Therapeutics, Inc.是一家基因编辑公司，专注于治愈性疗法的开发。该公司的体内项目包括 NTLA-2001，目前正在进行治疗转甲状腺素淀粉样变的 1 期临床试验；NTLA-2002 用于治疗遗传性血管性水肿；以及 NTLA-3001 用于与α-1 抗胰蛋白酶缺乏相关的肺病。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Intellia Therapeutics 更好的股票</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>Williams-Sonoma：一项基本面良好的买入机会</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Advance Auto Parts 因意外盈利而上涨</li>
<li>股票行业对成功投资的重要性</li>
<li>DraftKings 的三月疯狂失误：华尔街看到 +50% 的上涨空间</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Intellia Therapeutics 吗？</h2>
<p>在你考虑投资 Intellia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Intellia Therapeutics 并不在名单上。</p>
<p>虽然 Intellia Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Intellia治疗

<p>Intellia Therapeutics（纳斯达克代码：NTLA）股价在午盘交易中下跌 4.3%，至 9.06 美元，交易量显著减少。分析师意见不一，古根海姆将其目标价下调至 45 美元，而 HC Wainwright 则维持 30 美元的目标。该公司报告的季度每股亏损为 1.10 美元，超出预期，但收入同比下降 42.6%。机构投资者持有 88.77% 的股份，尽管近期表现不佳，但仍显示出强烈的投资兴趣</p>

<p>Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shares fell 4.3% during mid-day trading on Friday . The stock traded as low as $8.93 and last traded at $9.06. 436,341 shares traded hands during trading, a decline of 83% from the average session volume of 2,550,550 shares. The stock had previously closed at $9.46.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.（纳斯达克代码：NTLA - 获取免费报告）在周五的午盘交易中股价下跌了 4.3%。该股票最低交易价为 8.93 美元，最后交易价为 9.06 美元。在交易中，共成交 436,341 股，较平均交易量 2,550,550 股下降了 83%。该股票此前收盘价为 9.46 美元。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
</div><p>NTLA has been the topic of a number of analyst reports. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 12th. HC Wainwright restated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Wolfe Research upgraded shares of Intellia Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Barclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, February 28th. Finally, Wall Street Zen raised shares of Intellia Therapeutics to a &#34;sell&#34; rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $36.90.</p>
<div class="lb-trans"><p>NTLA 一直是多份分析师报告的主题。Guggenheim 将 Intellia Therapeutics 的目标价从 55.00 美元下调至 45.00 美元，并在 5 月 12 日的报告中给予该股票 “买入” 评级。HC Wainwright 在周二的研究报告中重申了 “买入” 评级，并对 Intellia Therapeutics 的股票设定了 30.00 美元的目标价。Wolfe Research 在 4 月 21 日的研究报告中将 Intellia Therapeutics 的股票评级从 “同业表现” 上调至 “跑赢大盘”，并设定了 21.00 美元的目标价。Barclays 在 2 月 28 日的报告中将 Intellia Therapeutics 的目标价从 55.00 美元下调至 26.00 美元，并给予该股票 “增持” 评级。最后，Wall Street Zen 在 3 月 3 日的研究报告中将 Intellia Therapeutics 的股票评级下调至 “卖出”。两位分析师给予该股票 “卖出” 评级，六位给予 “持有” 评级，十三位给予 “买入” 评级，还有一位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，Intellia Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 36.90 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on NTLA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 NTLA 的最新股票分析</strong></p>
</div><h2>Intellia Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 股票表现</h2>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票有望在 2025 年强势反弹</li>
</ul>
</div><p>The company has a market cap of $950.37 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. The business's 50 day moving average price is $7.98 and its 200-day moving average price is $10.63.</p>
<div class="lb-trans"><p>该公司的市值为 9.5037 亿美元，市盈率为-1.68，贝塔值为 2.33。该公司的 50 日移动平均价格为 7.98 美元，200 日移动平均价格为 10.63 美元。</p>
</div><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter last year, the firm posted ($1.12) earnings per share. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Intellia Therapeutics（纳斯达克代码：NTLA - 获取免费报告）最近在 5 月 8 日发布了其财报。该公司报告本季度每股收益为（1.10 美元），超出市场共识预期的（1.26 美元）0.16 美元。该公司本季度的收入为 1663 万美元，而分析师预期为 1139 万美元。去年同期，该公司每股收益为（1.12 美元）。Intellia Therapeutics 的收入同比下降了 42.6%。平均而言，股票研究分析师预计 Intellia Therapeutics, Inc.在当前财年将发布每股收益为-5.07 美元。</p>
</div><h2>Institutional Investors Weigh In On Intellia Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Intellia Therapeutics 的看法</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after buying an additional 44,022 shares in the last quarter. SG Americas Securities LLC raised its stake in Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after acquiring an additional 20,694 shares in the last quarter. KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after acquiring an additional 2,340 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after acquiring an additional 2,059 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $185,000. 88.77% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该股票的持股。Barclays PLC 在第三季度将其在 Intellia Therapeutics 的持股增加了 17.7%。Barclays PLC 现在拥有 292,795 股该公司的股票，价值 6,017,000 美元，此前在上个季度又购买了 44,022 股。SG Americas Securities LLC 在第四季度将其在 Intellia Therapeutics 的持股增加了 85.7%。SG Americas Securities LLC 现在拥有 44,838 股该公司的股票，价值 523,000 美元，此前在上个季度又收购了 20,694 股。KBC Group NV 在第四季度将其在 Intellia Therapeutics 的持股增加了 62.4%。KBC Group NV 现在拥有 6,093 股该公司的股票，价值 71,000 美元，此前在此期间又收购了 2,340 股。中国泛海资产管理有限公司在第四季度将其在 Intellia Therapeutics 的持股增加了 10.5%。中国泛海资产管理有限公司现在拥有 21,596 股该公司的股票，价值 252,000 美元，此前在此期间又收购了 2,059 股。最后，Empowered Funds LLC 在第四季度收购了 Intellia Therapeutics 的新股份，价值 185,000 美元。88.77% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Intellia Therapeutics</h2>
<div class="lb-trans"><h2>关于 Intellia Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.是一家基因编辑公司，专注于治愈性疗法的开发。该公司的体内项目包括 NTLA-2001，目前正在进行治疗转甲状腺素淀粉样变的 1 期临床试验；NTLA-2002 用于治疗遗传性血管性水肿；以及 NTLA-3001 用于与α-1 抗胰蛋白酶缺乏相关的肺病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>How to find penny stocks to invest and trade</li>
<li>Williams-Sonoma: A Fundamentally Good Buy On Sale Now</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Advance Auto Parts Jumps on Surprise Earnings Beat</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>DraftKings' March Madness Miss: Wall Street Sees +50% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Intellia Therapeutics 更好的股票</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>Williams-Sonoma：一项基本面良好的买入机会</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Advance Auto Parts 因意外盈利而上涨</li>
<li>股票行业对成功投资的重要性</li>
<li>DraftKings 的三月疯狂失误：华尔街看到 +50% 的上涨空间</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Intellia Therapeutics 吗？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Intellia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Intellia Therapeutics 并不在名单上。</p>
</div><p>While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intellia Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Intellia 治疗（NASDAQ:NTLA）股价下跌 4.3% - 现在是卖出的时候吗？